glp 1 weight loss drug Weight-loss drugs providing hope for some, but not for all GLP-1 Genetics: How Genes Affect

Findings have been heterogeneous: Some small studies reported improvements in repetitive behaviors and social responsiveness scale scores following chronic intranasal administration A large, multicenter NEJM-published phase 2 trial (SOARS-B) involving 290 children ages 3-17 found no significant improvement in social functioning compared to placebo over 24 weeks[11] A 2024 meta-analysis of 12 RCTs including 498 ASD participants found no statistically significant effect of oxytocin on social impairments in initial analysis, though dose-response analysis suggested higher doses may warrant further investigation fMRI studies have demonstrated neuroimaging differences in response to social stimuli following intranasal oxytocin, supporting central activity, even when behavioral outcomes are equivocal[12] Anxiety and Psychiatric Research Anxiety Disorders and PTSD Studies in anxious volunteers and clinical populations have investigated oxytocin for anxiolytic properties: Intranasal oxytocin reduced physiological stress responses (salivary cortisol, heart rate) in social stress paradigms Research in PTSD populations has examined potential for reduction of fear memory consolidation via amygdala modulation Pilot studies suggest possible benefit as an adjunct to exposure therapy, with the rationale that reduced amygdala hyperreactivity could facilitate fear extinction learning Schizophrenia Research Studies in schizophrenia patient populations have examined oxytocin as a potential adjunct to antipsychotic medication: Small randomized trials reported improved emotion recognition and social cognition scores following 8-week intranasal oxytocin protocols One study found that oxytocin, added to risperidone treatment, improved positive and negative syndrome scale social cognition subscores[13] Effect sizes have been modest and replication has been limited, leaving clinical utility unclear [CALLOUT BOX Highlighted] Critical Research Context: Oxytocin is unique among research peptides in having generated significant human clinical trial data including multiple Phase 2 randomized controlled trials

Intestinal microflora: negotiating health outcomes with the warring community within us

Expanded Benefits : Reduces emotional eating and stress-related cravings

Data Sources: We searched PubMed and Google Scholar for evidence on GLP-1 RAs and coronary events

Furthermore, in a phase 2 clinical trial addressing a patient group with type 2 diabetes and overweight/obesity, after 32 weeks of treatment, the cagrisema 2.4 mg group exhibited a more significant average weight loss compared to the cagrilintide 2.4 mg group or the group using semaglutide 2.4 mg alone, with reductions of 15.6%, 8.1%, and 5.1%, respectively